Toxic hepatitis case with prolonged jaundice due to Favipiravir

Favipiravir (FPV) is an antiviral drug used in the treatment of severe acute respiratory syndrome coronavirus 2 infection. The main side effects of this drug are teratogenicity and hyperuricemia. Limited information is available on other side effects. Here, we aimed to present our toxic hepatitis ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Yolacan, Ramazan, Karabulut, Umit, Uzel, Ali, Ucmak, Feyzullah, Kaya, Muhsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510735/
https://www.ncbi.nlm.nih.gov/pubmed/36177102
http://dx.doi.org/10.14744/hf.2022.2022.0007
_version_ 1784797505153662976
author Yolacan, Ramazan
Karabulut, Umit
Uzel, Ali
Ucmak, Feyzullah
Kaya, Muhsin
author_facet Yolacan, Ramazan
Karabulut, Umit
Uzel, Ali
Ucmak, Feyzullah
Kaya, Muhsin
author_sort Yolacan, Ramazan
collection PubMed
description Favipiravir (FPV) is an antiviral drug used in the treatment of severe acute respiratory syndrome coronavirus 2 infection. The main side effects of this drug are teratogenicity and hyperuricemia. Limited information is available on other side effects. Here, we aimed to present our toxic hepatitis case with prolonged jaundice after FPV treatment.
format Online
Article
Text
id pubmed-9510735
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-95107352022-09-28 Toxic hepatitis case with prolonged jaundice due to Favipiravir Yolacan, Ramazan Karabulut, Umit Uzel, Ali Ucmak, Feyzullah Kaya, Muhsin Hepatol Forum Case Report Favipiravir (FPV) is an antiviral drug used in the treatment of severe acute respiratory syndrome coronavirus 2 infection. The main side effects of this drug are teratogenicity and hyperuricemia. Limited information is available on other side effects. Here, we aimed to present our toxic hepatitis case with prolonged jaundice after FPV treatment. Kare Publishing 2022-09-23 /pmc/articles/PMC9510735/ /pubmed/36177102 http://dx.doi.org/10.14744/hf.2022.2022.0007 Text en © Copyright 2022 by Hepatology Forum https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Case Report
Yolacan, Ramazan
Karabulut, Umit
Uzel, Ali
Ucmak, Feyzullah
Kaya, Muhsin
Toxic hepatitis case with prolonged jaundice due to Favipiravir
title Toxic hepatitis case with prolonged jaundice due to Favipiravir
title_full Toxic hepatitis case with prolonged jaundice due to Favipiravir
title_fullStr Toxic hepatitis case with prolonged jaundice due to Favipiravir
title_full_unstemmed Toxic hepatitis case with prolonged jaundice due to Favipiravir
title_short Toxic hepatitis case with prolonged jaundice due to Favipiravir
title_sort toxic hepatitis case with prolonged jaundice due to favipiravir
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510735/
https://www.ncbi.nlm.nih.gov/pubmed/36177102
http://dx.doi.org/10.14744/hf.2022.2022.0007
work_keys_str_mv AT yolacanramazan toxichepatitiscasewithprolongedjaundiceduetofavipiravir
AT karabulutumit toxichepatitiscasewithprolongedjaundiceduetofavipiravir
AT uzelali toxichepatitiscasewithprolongedjaundiceduetofavipiravir
AT ucmakfeyzullah toxichepatitiscasewithprolongedjaundiceduetofavipiravir
AT kayamuhsin toxichepatitiscasewithprolongedjaundiceduetofavipiravir

Ejemplares similares